8 Analysts Have This to Say About AbbVie
Portfolio Pulse from Benzinga Insights
Over the last quarter, AbbVie (NYSE:ABBV) received 8 analyst ratings, with an average 12-month price target of $174.5, a high of $196.00, and a low of $150.00. The current average price target represents a 1.52% decrease from the previous average of $177.20. The ratings included 1 bullish, 5 somewhat bullish, and 2 indifferent, with no bearish or somewhat bearish ratings. Analysts typically review stocks quarterly or after major company updates, considering financial performance and market risks.
December 18, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie has received mostly positive ratings from analysts, with a slight decrease in the average price target over the last quarter. The consensus suggests a cautiously optimistic outlook for the stock.
The predominance of bullish and somewhat bullish ratings indicates a generally positive sentiment among analysts, which could lead to increased investor confidence and a potential short-term uplift in AbbVie's stock price. However, the slight decrease in the average price target may temper expectations slightly.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100